This observational study will assess the compliance and persistence of patients, real life efficacy and safety of intravenously quarterly administered 3 mg ibandronate \[Bonviva/Boniva\] in comparison to oral alendronate generics in female patients with post-menopausal osteoporosis. The anticipated time of assessment is 12 months. The target sample size is 5000-7000 patients.
Study Type
OBSERVATIONAL
Enrollment
6,054
As prescribed by physician
As prescribed by physician
Unnamed facility
Marburg, Germany
Assessment of compliance and persistence of Bonviva therapy: Number of prescriptions, number of applied injections, number of taken oral medication, continuation and duration of treatment
Time frame: 12 months
Pain intensity and reduction in use of analgesics
Time frame: 12 months
Quality of life and patients satisfaction
Time frame: 12 months
Degree of patient's mobility
Time frame: 12 months
Incidence of new osteoporotic fractures
Time frame: 12 months
Controllability and management of therapy by the physician
Time frame: 12 months
Patient baseline characteristics
Time frame: 12 months
User friendliness
Time frame: 12 months
Safety: AEs and SAEs
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.